Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-01-01

Study Completion Date

2024-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This retrospective observational study aims to evaluate the long-term survival of biologic therapies in adult patients with moderate-to-severe cutaneous psoriasis, with or without psoriatic arthritis, over a period of up to 10 years. The study investigates the influence of clinical, metabolic, and genetic factors, including SNPs and metabolic syndrome components, on treatment durability. Data were obtained from a single-centre cohort treated in routine clinical practice. This analysis seeks to identify predictors of therapeutic response and to explore pharmacogenetic profiles that may inform personalized treatment strategies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Analysis Of The Influence Of Metabolic Syndrome On Treatment Efficacy With Anti-Tnf In Moderate-Severe Psoriasis In Real Clinical Practice.

NCT01753245

Psoriasis Vulgaris Metabolic Syndrome

UNKNOWN

An Exploratory Genetic Study in Participants With Psoriasis

NCT02155192

Psoriasis

COMPLETED

Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis

NCT05125679

Psoriasis

TERMINATED PHASE4

Study of Psoriatic Arthritis

NCT00001420

Psoriasis Psoriatic Arthritis

COMPLETED

Etanercept Survival in Elderly Population

NCT02503059

Psoriasis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This retrospective observational cohort study investigates the influence of clinical, anthropometric, lifestyle, cardiometabolic, immunological, and genetic factors on the long-term effectiveness and durability of biologic therapies in patients with moderate-to-severe plaque psoriasis, with or without psoriatic arthritis.

The study includes adult patients diagnosed with plaque psoriasis who initiated treatment with a biologic agent between 2011 and 2021 at a tertiary academic dermatology center. All subjects were systematically assessed through standardized procedures, and follow-up data were collected over a period of up to 10 years. The primary endpoint is biologic drug survival (time to discontinuation), while secondary endpoints include treatment response (PGA), presence of psoriatic arthritis, nail psoriasis, and family history of psoriasis.

Clinical and biomarker data collected at baseline included:

Anthropometric variables: body mass index (BMI), waist circumference.

Lifestyle indicators: Mediterranean diet adherence (MEDAS), physical activity frequency, smoking and alcohol habits, and perceived stress scale.

Cardiovascular and metabolic status: history and treatment of hypertension, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome, following ATP III/NCEP criteria.

Cardiometabolic biomarkers: leptin, adiponectin, insulin, lipoprotein(a), and HOMA-IR.

Inflammatory profile: a multiplex panel of cytokines and chemokines (including IL-1β, IL-6, IL-8, IL-17, IL-23, TNF-α, IFN-γ, MCP-1, IP-10).

Microparticles: circulating endothelial and platelet-derived microparticles quantified by flow cytometry.

Genotyping was performed using a custom array targeting 450 SNPs in 65 candidate genes previously associated with psoriasis susceptibility, systemic inflammation, and cardiometabolic risk (e.g., IL12B, IL23R, TNFAIP3, TRAF3IP2, HLA-C, CDKAL1, TCF7L2). Quality control included filtering by call rate, Hardy-Weinberg equilibrium, and minor allele frequency (MAF \> 5%).

Data integration and quality assurance:

Clinical, laboratory, and genotyping data were integrated using unique patient identifiers.

A complete data dictionary was compiled, with defined variable sources, coding rules (e.g., WHO-ATC for drugs), and standard ranges.

Logical and range-based data checks were conducted. Variables with implausible values (e.g., negative survival time) were excluded or corrected.

A pre-specified imputation plan was applied to address missingness: median or mode imputation for clinical variables; multiple imputation for biomarkers where appropriate.

Variables were harmonized across data sources to ensure consistent definitions and temporal alignment.

All analyses adhered to a predefined statistical analysis plan.

Sample size and power: With over 800 patients and a median follow-up of 5+ years, the study has sufficient statistical power (\>80%) to detect hazard ratios of \~1.5 for binary predictors with moderate prevalence (≥20%).

Statistical analysis:

Cox proportional hazards regression was used to assess the association between predictors and biologic drug survival.

Models were adjusted for potential confounders such as age, gender, and comorbidities.

Univariate models were conducted for each clinical and lifestyle variable, excluding SNPs, with false discovery rate (FDR) adjustment.

Stratified analyses were conducted by drug class (e.g., anti-TNF, anti-IL17, anti-IL12/23) and individual drug.

Pharmacogenetic analyses were conducted separately using additive models for each SNP, with interaction testing for cardiometabolic traits.

Results were summarized as hazard ratios (HR) with 95% confidence intervals and adjusted p-values.

All procedures followed STROBE guidelines for observational research. The study protocol was reviewed and approved by the Institutional Ethics Committee, and all patients provided written informed consent for biobanking and retrospective analysis of anonymized data.

This study aims to identify actionable clinical and genetic predictors of biologic therapy durability in real-world psoriasis, contributing to personalized treatment strategies and understanding of cardio-dermatologic interactions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis Psoriatic Arthritis (PsA) Cardiovascular Risk Factors Metabolic Syndrome (MetS) Drug Survival Pharmacogenetics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Psoriasis Cohort - Observational Follow-up

Adult patients with a confirmed diagnosis of plaque psoriasis, with or without psoriatic arthritis, who initiated biologic therapy between 2010 and 2020 at tertiary dermatology clinics in Spain. Participants were followed retrospectively for up to 10 years to assess treatment survival, safety, and disease outcomes. The study explores the influence of genetic variants (450 SNPs across 65 genes), cardiometabolic comorbidities, lifestyle factors, and circulating biomarkers (adipokines, cytokines, microparticles) on treatment durability and response. No interventions were assigned by protocol.

Biologic therapy for psoriasis

Intervention Type DRUG

Exposure to systemic biologic drugs for psoriasis, including TNF inhibitors (etanercept, adalimumab, infliximab, certolizumab), IL-12/23 inhibitors (ustekinumab), IL-17 inhibitors (secukinumab, ixekizumab, brodalumab), and IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab). Treatments were prescribed as part of routine clinical care.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biologic therapy for psoriasis

Exposure to systemic biologic drugs for psoriasis, including TNF inhibitors (etanercept, adalimumab, infliximab, certolizumab), IL-12/23 inhibitors (ustekinumab), IL-17 inhibitors (secukinumab, ixekizumab, brodalumab), and IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab). Treatments were prescribed as part of routine clinical care.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Anti-TNF, Anti-IL-12/23, Anti-IL-17, Anti-IL-23

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults (≥18 years) diagnosed with moderate-to-severe cutaneous psoriasis.
* Initiation of treatment with a biologic agent between 2010 and 2020.
* Minimum follow-up of 12 months or until drug discontinuation.
* Availability of clinical and treatment data at baseline.
* Availability of at least one blood sample for biomarker/genetic analysis.
* Informed consent obtained for biobanking and genetic analyses.

Exclusion Criteria

* Diagnosis of other chronic inflammatory skin diseases (e.g., atopic dermatitis, lupus).
* Concomitant participation in interventional clinical trials at baseline.
* Patients with incomplete treatment history or missing survival data.
* Systemic immunosuppressive therapy (e.g., cyclosporine, methotrexate) without biologics during the study period.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No